LC
MDGL icon

Lindbrook Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Lindbrook Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$10.3K Buy
31
+5
+19% +$1.64K ﹤0.01% 1641
2024
Q4 		$8.02K Buy
26
+8
+44% +$2.25K ﹤0.01% 1769
2024
Q3 		$3.82K Sell
18
-13
-42% -$3.33K ﹤0.01% 2127
2024
Q2 		$8.69K Buy
31
+21
+210% +$5K ﹤0.01% 1704
2024
Q1 		$2.67K Sell
10
-15
-60% -$3.53K ﹤0.01% 2142
2023
Q4 		$5.79K Buy
25
+22
+733% +$3.85K ﹤0.01% 1812
2023
Q3 		$438 Buy
+3
New +$565 ﹤0.01% 2562
2023
Q1 		– Sell
-25
Closed -$7.26K – 2858
2022
Q4 		$7.26K Buy
25
+12
+92% +$1.17K ﹤0.01% 1596
2022
Q3 		$1K Sell
13
-9
-41% -$625 ﹤0.01% 2402
2022
Q2 		$2K Sell
22
-17
-44% -$1.25K ﹤0.01% 1992
2022
Q1 		$4K Buy
+39
New +$3.29K ﹤0.01% 1714
2021
Q2 		– Sell
-4
Closed – – 1965
2021
Q1 		$0 Buy
+4
New +$466 ﹤0.01% 1913

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lindbrook Capital's MDGL Position: Q1 2025 in Review

Lindbrook Capital increased its Madrigal Pharmaceuticals (MDGL) stake by 19% in Q1 2025, buying an estimated $1.64K and bringing the position to 31 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1641.

Lindbrook Capital first reported a position in MDGL in Q1 2021 and has held it in 12 quarters since. 321 funds tracked by Wall St. Rank hold MDGL as of Q1 2025.

  • Lindbrook Capital held 31 shares of Madrigal Pharmaceuticals worth $10.3K as of Q1 2025.
  • Lindbrook Capital bought 5 Madrigal Pharmaceuticals shares in Q1 2025, an estimated $1.64K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1641 holding.
  • Lindbrook Capital first reported a position in Madrigal Pharmaceuticals in Q1 2021 and has held it in 12 quarters since.
  • 321 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.